Lantheus Holdings, Inc. (NASDAQ: LNTH) Securities Fraud Class Action

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) common stock between July 10, 2024 and August 5, 2025, inclusive (the “Class Period”).

Lantheus is a global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Lantheus’ key Radiopharmaceutical Oncology product is PYLARIFY, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.

The  complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Lantheus provided investors with misleading statements concerning the true state of PYLARIFY’s competitive position, notably, that Lantheus was not equipped to properly assess the pricing and competitive dynamics for PYLARIFY; (2) Lantheus failed to properly disclose that its early 2025 price increase, issued despite price erosion the year prior, created an opportunity for competitive pricing to flourish, risking PYLARIFY’s price point, revenue, and overall growth potential; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:
On May 11, 2026, Defendants filed a Motion to Dismiss the Amended Complaint. The Motion is currently being briefed by the parties. This action is ongoing.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.